Company Overview and News

9
Sanjay Sharma resigns as head of Deutsche Bank’s i-banking unit

2018-06-18 livemint
Mumbai: Sanjay Sharma, managing director and head of equity capital markets at Deutsche Bank’s Indian investment banking unit, has resigned, two people aware of the development said.
DB BHRYY 534816 INFRATEL CLNDY 533278 COALINDIA JSWENERGY 533148

0
Bharti Infratel Limited - Investor Presentation

2018-06-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BHRYY 534816 INFRATEL

0
Bhopal: More than fifty per cent BSCDCL smart poles non functional

2018-06-07 freepressjournal.in
Bhopal: The smart poles which the Bhopal smart city development corporation limited (BSCDCL) had started installing across the city in June 2017, are yet to start operations. As many as 98 such poles have been installed till date and more than fifty per cent of the poles are non-functional.
BHRYY 534816 INFRATEL

34
Market Update: HDFC Bank jumps 2%, hits fresh 52-week high; Rcom jumps 10%

2018-05-31 moneycontrol
The broader indices are trading on a positive note this Thursday morning with the Nifty up 26 points at 10,641 and the Sensex trading higher by 88 points at 34,994.
BHRYY 500325 BHUSANSTL RELIANCE ICLQY 533155 532712 BHRQY TTNQY JUBLFOOD 533278 511288 500470 532540 RCOM 534816 RIGD JBLWY HDFCBANK GAILF INFRATEL BHARTIARTL CLNDY 500055 RLNIY GRUH KMBKY GRHFY 532822 539207 532454 TTST TATASTEEL TATLY HDB 500180 GAILY KOTAKBANK IDEA TCS 500247 COALINDIA MANPASAND

2
Bharti Infratel falls to over 1-year low

2018-05-29 thehindubusinessline
Technicals suggested that the stock may fall up to Rs 281.75, the 100 per cent retracement of the uptrend.
533106 BHRYY OIL 534816 INFRATEL

26
Nifty rallies for 3rd day on oil slide, rupee gain; Sensex closes up 241 pts, midcaps outperform

2018-05-28 moneycontrol
Benchmark indices started off the week on a strong note, rallying for third consecutive session following sharp slide in crude oil prices and recovery in rupee.
BHRYY 532617 HCTHY TCHQY 532978 532755 532215 AXISBANK 534816 532281 HDFCBANK BJJQY INFRATEL 500034 INDIGO AXB IBN JETAIRWAYS 539207 TECHM 539448 AXBKY AXBA ICICIBANK BAJAJFINSV BAJFINANCE HDB 532174 500180 HCLTECH MANPASAND

46
Bulls roar: Sensex gains 261 pts; Nifty Midcap up 360 pts amid sharp gains in rupee, fall in oil

2018-05-27 moneycontrol
Bulls retained charge at Dalal Street for the second consecutive session on Friday as the Sensex gained more than 300 points intraday. The rally was driven by banking & financials, auto, metals, oil and pharma stocks.
PAGEIND 590003 BHUSANSTL TCHQY 532755 CADILAHC 535789 532321 GSCLCEMENT 534816 BJJQY 500570 EICHERMOT CLNDY 500055 PGDQY 532827 YYBKY 518029 TECHM BAJAJFINSV BAJFINANCE TATASTEEL TATLY 500180 KOTAKBANK COALINDIA BHRYY IDBI 532978 533278 505200 500470 INFRATEL HDFCBANK TATAMOTORS 500034 YESBANK ECQRY 500116 KMBKY IBN IDKQY 532648 CDLYY IBULHSGFIN ICICIBANK TTST HDB 532174 500247 KARURVYSYA TTM

18
Why The Negativity Over Vodafone?

2018-05-23 seekingalpha
Vodafone is a high yield company that released its 2018 Full Year Results on the 15th May.
0941 BHRYY CHLKF VOD VOD CHL VODPF 534816 IDEA ICLQY INFRATEL 532822

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...